Sobi and Horizon Pharma enter five-year distribution agreement for Ravicti® and Ammonaps® outside the United States

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Horizon Pharma plc (NASDAQ: HZNP) (“Horizon”) today announced that the companies have entered into a...

Read more

Sobi gains commercial rights for Relistor®, Deflux® and Solesta® from PharmaSwiss

Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced that the company has gained commercial rights from the Swiss based company...

Read more

Xiapex approved by the EU Commission for the treatment of Peyronie's disease

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that the EU Commission has approved Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. Peyronie's disease is a condition that involves the development of collagen plaque, or scar tissue, on the shaft of the penis.

Read more

Sobi extends and restructures distribution agreement with Exelixis for Cometriq

Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) today announced that their agreement with Exelixis, Inc. has been restructured and extended to 31 December 2019. Sobi is responsible for the commercialisation and distribution of Cometriq® (cabozantinib) for progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC) in the European Union (EU), Switzerland, Norway, Russia, and Turkey. The companies established the collaboration in February 2013, which was initially structured to expire 31 December 2015.

Read more

Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease

Swedish Orphan Biovitrum AB (publ) (Sobi) and partner Auxilium Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the use of Xiapex® (collagenase clostridium histolyticum) for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.

Read more

PHARMING AND SWEDISH ORPHAN BIOVITRUM AMEND AND EXTEND RUCONEST DISTRIBUTION AGREEMENT

PHARMING TO DIRECTLY COMMERCIALISE RUCONEST IN AUSTRIA, GERMANY AND NETHERLANDS

Read more

Sobi Vice-Presidents write article about European Challenge

Dr Stefan Fraenkel, MBA, PhD, Ass Prof and Senior Vice-President and Head of Corporate Development and Dr Anders Edvell, MD, MBA, PhD and...

Read more

Sobi files for EU approval of Xiapex for Peyronies disease

Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc.today announced that Sobi has filed for an extension of the label for...

Read more

Sobi becomes market authorisation holder for Xiapex in Europe

Stockholm, Sweden and Chesterbrook, Pa., 7 April, 2014 -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL)...

Read more

Sobi enters partnership with Tigenix for the commercialisation of ChondroCelect

Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company has acquired the licencing rights to market and distribute ChondroCelect, a...

Read more